You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A retrospective cohort study uncovered microRNA signatures that could tell lung cancer patients apart from others, including patients with other, non-tumor lung conditions.
In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.
In PNAS this week: gene-edited mouse model of small cell lung cancer, cystic fibrosis carrier-related conditions, and more.
The firm said that its cell-free DNA assay has shown a high positive predictive value in preliminary clinical studies involving stage IV colorectal cancer patients.
Catalyst will use Biocept's liquid biopsy platform to screen for cancer in patients in a clinical study of its rare disease drug Firdapse.
The circulating tumor cell-based classifier had an overall accuracy of 89 percent for small-cell lung cancer patients, the researchers reported.
In PLOS this week: evolutionary history of polyomaviruses, mutations linked to colon cancer progression, and more.
In PNAS this week: Denisovan DNA sequences, genome sequencing study of Chagas vector, and more
In Nature this week: two loci linked to depression, CRISPR/Cas9-based study of diarrhea-causing microbe, and more.
A comprehensive genomic profiling of small cell lung cancer has found that nearly all tumors harbor inactivated TP53 and RB1 genes, along with other genetic mutations.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.